Recent Patents on Anti-Cancer Drug Discovery

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back Subscribe
Research Article

UBE2L3 Suppresses Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression

Author(s): Xiwu Zhao, Guoqiang Shan, Deguo Xing, Hongwei Gao, Zhenggang Xiong, Wenpeng Hui and Mingzhi Gong*

Volume 20, Issue 1, 2025

Published on: 21 February, 2024

Page: [102 - 112] Pages: 11

DOI: 10.2174/0115748928297557240212112531

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: Osteosarcoma is a highly invasive bone marrow stromal tumor with limited treatment options. Oxidative stress plays a crucial role in the development and progression of tumors, but the underlying regulatory mechanisms are not fully understood. Recent studies have revealed the significant involvement of UBE2L3 in oxidative stress, but its specific role in osteosarcoma remains poorly investigated.

Objective: This study aimed to explore the molecular mechanisms by which UBE2L3 promotes oxidative stress-regulated necroptosis to accelerate the progression of osteosarcoma using in vitro cell experiments.

Methods: Human osteoblast hFOB1.19 cells and various human osteosarcoma cell lines (MG-63, U2OS, SJSA-1, HOS, and 143B) were cultured in vitro. Plasmids silencing UBE2L3 and negative control plasmids were transfected into U2OS and HOS cells. The cells were divided into the following groups: U2OS cell group, HOS cell group, si-NC-U2OS cell group, si-UBE2L3-U2OS cell group, si-NC-HOS cell group, and si-UBE2L3-HOS cell group. Cell viability and proliferation capacity were measured using the Tunnel method and clonogenic assay. Cell migration and invasion abilities were assessed by Transwell and scratch assays. Cell apoptosis was analyzed by flow cytometry, and ROS levels were detected using immunofluorescence. The oxidative stress levels in various cell groups and the expression changes of necroptosis-related proteins were assessed by PCR and WB. Through these experiments, we aim to evaluate the impact of oxidative stress on necroptosis and uncover the specific mechanisms by which targeted regulation of oxidative stress promotes tumor cell necroptosis as a potential therapeutic strategy for osteosarcoma.

Results: The mRNA expression levels of UBE2L3 in human osteosarcoma cell lines were significantly higher than those in human osteoblast hFOB1.19 cells (p <0.01). UBE2L3 expression was significantly decreased in U2OS and HOS cells transfected with si-UBE2L3, indicating the successful construction of stable cell lines with depleted UBE2L3. Tunnel assay results showed a significant increase in the number of red fluorescent-labeled cells in si-UBE2L3 groups compared to si-NC groups in both cell lines, suggesting a pronounced inhibition of cell viability. Transwell assay demonstrated a significant reduction in invasion and migration capabilities of si-UBE2L3 groups in osteosarcoma cells. The clonogenic assay revealed significant suppression of proliferation and clonogenic ability in both U2OS and HOS cells upon UBE2L3 knockdown. Flow cytometry confirmed that UBE2L3 knockdown significantly enhanced apoptosis in U2OS and HOS cells. Immunofluorescence results showed that UBE2L3 silencing promoted oxidative stress levels in osteosarcoma cells and facilitated tumor cell death. WB analysis indicated a significant increase in phosphorylation levels of necroptosis-related proteins, RIP1, RIP3, and MLKL, in both osteosarcoma cell lines after UBE2L3 knockdown. In addition, the expression of necrosis-associated proteins was inhibited by the addition of the antioxidant N-acetylcysteine (NAC).

Conclusion: UBE2L3 is upregulated in osteosarcoma cells, and silencing of UBE2L3 promotes oxidative stress in these cells, leading to enhanced necroptosis and delayed progression of osteosarcoma.

Keywords: Osteosarcoma, oxidative stress, necroptosis, UBE2L3, ROS, apoptosis.

[1]
Wu X, Wang J, He D. Establishment and validation of a competitive risk model for predicting cancer-specific survival in patients with osteosarcoma: A population-based study. J Cancer Res Clin Oncol 2023; 149(17): 15383-94.
[http://dx.doi.org/10.1007/s00432-023-05320-x] [PMID: 37639006]
[2]
Xu Y, Shi F, Zhang Y, et al. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors. Int J Cancer 2023; 154(2): 226-40.
[http://dx.doi.org/10.1002/ijc.34694] [PMID: 37596989]
[3]
Shao Z, Bi S. Studies related to osteosarcoma and metabolism from 1990 to 2022: A visual analysis and bibliometric study. Front Endocrinol 2023; 14: 1144747.
[http://dx.doi.org/10.3389/fendo.2023.1144747] [PMID: 36950694]
[4]
Almansa-Gómez S, Prieto-Ruiz F, Cansado J, Madrid M. Autophagy modulation as a potential therapeutic strategy in osteosarcoma: Current insights and future perspectives. Int J Mol Sci 2023; 24(18): 13827.
[http://dx.doi.org/10.3390/ijms241813827] [PMID: 37762129]
[5]
Mengjun MA, Hongyu LI . Application of anti-SIRPA antibody combined with arginase in preparation of osteosarcoma treatment drug. CN117065015, 2023. 2023-11-17.
[6]
Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: A review of current and future strategies. Int J Mol Sci 2020; 21(18): 6885.
[http://dx.doi.org/10.3390/ijms21186885] [PMID: 32961800]
[7]
Li J, Yang Z, Li Y, et al. Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment. Oncotarget 2016; 7(28): 44763-78.
[http://dx.doi.org/10.18632/oncotarget.8206] [PMID: 27007056]
[8]
Meng Q, Zhang W, Xu X, et al. The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124. Int J Mol Med 2018; 41(5): 2968-76.
[http://dx.doi.org/10.3892/ijmm.2018.3458] [PMID: 29436576]
[9]
Yang S, Xiao H, Sun Y, Cao L. Zeylenone synergizes with cisplatin in osteosarcoma by enhancing DNA damage, apoptosis, and necrosis via the Hsp90/ AKT / GSK3β and Fanconi anaemia pathway. Phytother Res 2021; 35(10): 5899-918.
[http://dx.doi.org/10.1002/ptr.7299] [PMID: 34585447]
[10]
Huang C, Lin ZJ, Lee CJ, Lai WH, Chen JC, Huang HC. ε-Viniferin and α-viniferin alone or in combination induced apoptosis and necrosis in osteosarcoma and non-small cell lung cancer cells. Food Chem Toxicol 2021; 158: 112617.
[http://dx.doi.org/10.1016/j.fct.2021.112617] [PMID: 34728247]
[11]
Tao NN, Zhang ZZ, Ren JH, et al.   Overexpression   of   ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3β/p65 pathway. Cancer Lett 2020; 481: 1-14.
[http://dx.doi.org/10.1016/j.canlet.2020.03.028] [PMID: 32268166]
[12]
Reyes-Hernández OD, Mejía-García A, Sánchez-Ocampo EM, et al. Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: Implications for p53 ubiquitination. Biochem Pharmacol 2010; 80(6): 932-40.
[http://dx.doi.org/10.1016/j.bcp.2010.05.007] [PMID: 20478272]
[13]
Hou X, Yang S, Yin J. Blocking the REDD1/TXNIP axis ameliorates LPS-induced vascular endothelial cell injury through repressing oxidative stress and apoptosis. Am J Physiol Cell Physiol 2019; 316(1): C104-10.
[http://dx.doi.org/10.1152/ajpcell.00313.2018] [PMID: 30485138]
[14]
Wang H, Li J, Li X. Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma. Aging 2023; 15(11): 4820-43.
[http://dx.doi.org/10.18632/aging.204764] [PMID: 37285835]
[15]
Gandhi D, Naoghare PK, Bafana A, Kannan K, Sivanesan S. Fluoride-induced oxidative and inflammatory stress in osteosarcoma cells: Does it affect bone development pathway? Biol Trace Elem Res 2017; 175(1): 103-11.
[http://dx.doi.org/10.1007/s12011-016-0756-6] [PMID: 27234253]
[16]
Yao ZK, Jean YH, Lin SC, et al. Manoalide induces intrinsic apoptosis by oxidative stress and mitochondrial dysfunction in human osteosarcoma cells. Antioxidants 2023; 12(7): 1422.
[http://dx.doi.org/10.3390/antiox12071422] [PMID: 37507960]
[17]
Tornín J, Villasante A, Solé-Martí X, Ginebra MP, Canal C. Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer stem cell properties. Free Radic Biol Med 2021; 164: 107-18.
[http://dx.doi.org/10.1016/j.freeradbiomed.2020.12.437] [PMID: 33401009]
[18]
Yang J, Zhang A, Luo H, Ma C. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. Sci Rep 2022; 12(1): 1279.
[http://dx.doi.org/10.1038/s41598-022-05341-5] [PMID: 35075228]
[19]
Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 2021; 500: 1-10.
[http://dx.doi.org/10.1016/j.canlet.2020.12.024] [PMID: 33359211]
[20]
Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma. Nat Rev Dis Primers 2022; 8(1): 77.
[http://dx.doi.org/10.1038/s41572-022-00409-y] [PMID: 36481668]
[21]
Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med 2021; 385(22): 2066-76.
[http://dx.doi.org/10.1056/NEJMra2103423] [PMID: 34818481]
[22]
He F, Zhang W, Shen Y, et al. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg 2016; 36(Pt A): 283-92.
[http://dx.doi.org/10.1016/j.ijsu.2016.11.016] [PMID: 27840310]
[23]
Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 2021; 18(10): 609-24.
[http://dx.doi.org/10.1038/s41571-021-00519-8] [PMID: 34131316]
[24]
Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: A review of current and future therapeutic approaches. Biomed Eng Online 2021; 20(1): 24.
[http://dx.doi.org/10.1186/s12938-021-00860-0] [PMID: 33653371]
[25]
Wei N, Chao-yang G, Wen-ming Z, et al. A ubiquitin-related gene signature for predicting prognosis and constructing molecular subtypes in osteosarcoma. Front Pharmacol 2022; 13: 904448.
[http://dx.doi.org/10.3389/fphar.2022.904448] [PMID: 36060009]
[26]
Rajendra R, Malegaonkar D, Pungaliya P, et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem 2004; 279(35): 36440-4.
[http://dx.doi.org/10.1074/jbc.C400300200] [PMID: 15247280]
[27]
Zhang X, Huo C, Liu Y, Su R, Zhao Y, Li Y. Mechanism and disease association with a ubiquitin conjugating E2 enzyme: UBE2L3. Front Immunol 2022; 13: 793610.
[http://dx.doi.org/10.3389/fimmu.2022.793610] [PMID: 35265070]
[28]
Fu B, Li S, Wang L, Berman MA, Dorf ME. The ubiquitin conjugating enzyme UBE2L3 regulates TNFα-induced linear ubiquitination. Cell Res 2014; 24(3): 376-9.
[http://dx.doi.org/10.1038/cr.2013.133] [PMID: 24060851]
[29]
Cortizo AM, Bruzzone L, Molinuevo S, Etcheverry SB. A possible role of oxidative stress in the vanadium-induced cytotoxicity in the MC3T3E1 osteoblast and UMR106 osteosarcoma cell lines. Toxicology 2000; 147(2): 89-99.
[http://dx.doi.org/10.1016/S0300-483X(00)00181-5] [PMID: 10874156]
[30]
Condos TEC, Dunkerley KM, Freeman EA, et al. Synergistic recruitment of UbcH7~Ub and phosphorylated Ubl domain triggers parkin activation. EMBO J 2018; 37(23): e100014.
[http://dx.doi.org/10.15252/embj.2018100014] [PMID: 30446597]
[31]
Camarillo GF, Goyon EI, Zuñiga RB, Salas LAS, Escárcega AEP, Yamamoto-Furusho JK. Gene expression profiling of mediators associated with the inflammatory pathways in the intestinal tissue from patients with ulcerative colitis. Mediators Inflamm 2020; 2020: 1-11.
[http://dx.doi.org/10.1155/2020/9238970] [PMID: 32410873]
[32]
Garva R, Thepmalee C, Yasamut U, et al. Sirtuin family members selectively regulate autophagy in osteosarcoma and mesothelioma cells in response to cellular stress. Front Oncol 2019; 9: 949.
[http://dx.doi.org/10.3389/fonc.2019.00949] [PMID: 31608237]
[33]
Kurz T, Terman A, Brunk UT. Autophagy, ageing and apoptosis: The role of oxidative stress and lysosomal iron. Arch Biochem Biophys 2007; 462(2): 220-30.
[http://dx.doi.org/10.1016/j.abb.2007.01.013] [PMID: 17306211]
[34]
Hanus J, Anderson C, Wang S. RPE necroptosis in response to oxidative stress and in AMD. Ageing Res Rev 2015; 24(Pt B): 286-98.
[http://dx.doi.org/10.1016/j.arr.2015.09.002]

Rights & Permissions Print Cite